Abiopharma

🔍 Chang Michael L. (Executive)

Company: Nutex Health Inc. (NUTX)

Report Date: 2026-03-09

Detailed Transactions and Holdings:

• Acquired 2,084 shares of Common Stock (Direct)
  Date: 2026-03-10 | Code: M | equity_swap_involved: 0 | shares_owned_after: 83,125.00 | transaction_form_type: 4 | Footnotes: F1, F1, F3
• Sold 769 shares of Common Stock at $86.2224 per share (Direct)
  Date: 2026-03-10 | Code: F | equity_swap_involved: 0 | shares_owned_after: 82,356.00 | transaction_form_type: 4 | Footnotes: F2, F3
• Acquired 1,936 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-10 | Code: M | Expires: 2029-03-01 | Exercise: 2027-03-01 | equity_swap_involved: 0 | shares_owned_after: 5,621.00 | transaction_form_type: 4 | Footnotes: F1, F1, F4, F4

Footnotes:

• F1: Restricted stock units convert into common stock on a one-for-one basis.
• F2: Of the 2,084 shares issued subsequent to vesting, 769 shares were sold to cover tax withholding obligations.
• F3: Michael Chang PLLC ("CHANG") is the direct beneficial owner of 82,356 shares of Common Stock. Dr. Chang as the 100% owner and sole manager of CHANG, is an indirect beneficial owner of such shares. Dr. Chang is the direct owner of 984 shares.
• F4: On March 10, 2026, the Reporting Person was granted 1,936 RSUs, which vest in three equal installments on March 1, 2027, March 1, 2028, and March 1, 2029.